Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
2.
BMJ Case Rep ; 20182018 May 30.
Artículo en Inglés | MEDLINE | ID: mdl-29848540

RESUMEN

A 59-year-old woman presented with a sudden onset of breathlessness and chest pain. An echocardiography and CT scan showed pulmonary embolism and infarction with a paradoxical thrombus visualised in both atria. For haemodynamically stable patients, the optimal management strategy is poorly defined. Three main strategies were considered: surgical thrombectomy, thrombolysis and anticoagulation. Surgery with reversal of anticoagulation may lead to further coagulation and increased risk of bleeding complications. The significant pulmonary hypertension and right ventricular infarction raised the prospect of difficult weaning from cardiopulmonary bypass following thrombectomy. Thrombolysis, which has significant mortality rate, and systemic embolisation including pulmonary infarction with haemorrhagic transformation were also contraindications. A multidisciplinary approach was adopted and anticoagulation was therefore believed to be the safest and effective approach. Here, the use of anticoagulation alone was fortunately successful but could as easily end in disaster. This approach should be considered the ideal paradigm to yield optimum outcomes.


Asunto(s)
Anticoagulantes/uso terapéutico , Cardiopatías/tratamiento farmacológico , Embolia Pulmonar/tratamiento farmacológico , Trombosis/tratamiento farmacológico , Angiografía por Tomografía Computarizada , Quimioterapia Combinada , Embolia Paradójica/diagnóstico por imagen , Embolia Paradójica/tratamiento farmacológico , Femenino , Atrios Cardíacos , Cardiopatías/diagnóstico por imagen , Heparina/uso terapéutico , Humanos , Persona de Mediana Edad , Embolia Pulmonar/diagnóstico por imagen , Infarto Pulmonar/diagnóstico por imagen , Infarto Pulmonar/tratamiento farmacológico , Trombosis/diagnóstico por imagen , Resultado del Tratamiento , Warfarina/uso terapéutico
5.
Asian Cardiovasc Thorac Ann ; 23(3): 332-4, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24757179

RESUMEN

Esophageal duplication cyst is a rare congenital mediastinal cyst. Most of these cysts become symptomatic in childhood and only rare cases remain asymptomatic until adolescence. They may produce symptoms due to esophageal and respiratory system compression, rupture, and infection. A 25-year-old man presented with pulmonary infection and bronchiectasis that did not improve with medical treatment. A diagnosis of esophageal duplication cyst was made intraoperatively.


Asunto(s)
Bronquiectasia/etiología , Quiste Esofágico/diagnóstico , Esófago/anomalías , Infarto Pulmonar/etiología , Enfermedades Raras/diagnóstico , Toracotomía , Adulto , Antiinfecciosos/uso terapéutico , Bronquiectasia/tratamiento farmacológico , Diagnóstico Diferencial , Quiste Esofágico/complicaciones , Quiste Esofágico/cirugía , Esófago/cirugía , Humanos , Masculino , Infarto Pulmonar/tratamiento farmacológico , Enfermedades Raras/complicaciones , Enfermedades Raras/cirugía , Insuficiencia del Tratamiento
6.
Am J Respir Crit Care Med ; 190(1): 9-18, 2014 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-24713029

RESUMEN

Tuberculosis (TB), a chronic infectious disease of global importance, is facing the emergence of drug-resistant strains with few new drugs to treat the infection. Pulmonary cavitation, the hallmark of established disease, is associated with very high bacillary burden. Cavitation may lead to delayed sputum culture conversion, emergence of drug resistance, and transmission of the infection. The host immunological reaction to Mycobacterium tuberculosis is implicated in driving the development of TB cavities. TB is characterized by a matrix-degrading phenotype in which the activity of proteolytic matrix metalloproteinases (MMPs) is relatively unopposed by the specific tissue inhibitors of metalloproteinases. Proteases, in particular MMPs, secreted from monocyte-derived cells, neutrophils, and stromal cells, are involved in both cell recruitment and tissue damage and may cause cavitation. MMP activity is augmented by proinflammatory chemokines and cytokines, is tightly regulated by complex signaling paths, and causes matrix destruction. MMP concentrations are elevated in human TB and are closely associated with clinical and radiological markers of lung tissue destruction. Immunomodulatory therapies targeting MMPs in preclinical and clinical trials are potential adjuncts to TB treatment. Strategies targeting patients with cavitary TB have the potential to improve cure rates and reduce disease transmission.


Asunto(s)
Antituberculosos/uso terapéutico , Inmunomodulación/fisiología , Metaloproteinasas de la Matriz/efectos de los fármacos , Mycobacterium tuberculosis/efectos de los fármacos , Infarto Pulmonar/etiología , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Tuberculosis Pulmonar/tratamiento farmacológico , Animales , Antituberculosos/administración & dosificación , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Sistemas de Liberación de Medicamentos , Salud Global , Humanos , Metaloproteinasas de la Matriz/análisis , Metaloproteinasas de la Matriz/inmunología , Infarto Pulmonar/tratamiento farmacológico , Infarto Pulmonar/inmunología , Tuberculosis Resistente a Múltiples Medicamentos/inmunología , Tuberculosis Resistente a Múltiples Medicamentos/transmisión , Tuberculosis Pulmonar/complicaciones , Tuberculosis Pulmonar/inmunología
7.
Eur Rev Med Pharmacol Sci ; 17(24): 3341-6, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24379066

RESUMEN

Patients with chronic diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and diabetes mellitus, are exposed to particular complications that require a careful diagnostic algorithm. Pulmonary Embolism (PE) in COPD patients often demands an accurate differential diagnosis and a prompt therapeutic intervention. Aspergillus spp. infection comprises a large spectrum of pathological manifestations, depending on immune status and the presence of underlying lung disease. These manifestations may range from invasive pulmonary aspergillosis (IPA) in gravely immunocompromised patients, to chronic necrotizing aspergillosis (CNA) in patients with chronic lung diseases and moderately compromised immune systems. Aspergilloma is generally observed in patients with cavitary lung diseases, and allergic bronchopulmonary aspergillosis (ABPA) is reported in patients with hypersensitivity to Aspergillus antigens. We report a case with pulmonary aspergillosis arisen on a pulmonary infarction after PE in a patient with COPD and diabetes mellitus. To date, report with this clinical evolution was not reported in literature. This report is intended to describe an accurate diagnostic path in a complex overlap of different pathological conditions, highlighting the great importance of differential diagnosis and an appropriate diagnostic algorithm. In addition, open issues on the real diagnostic value of clinical, radiological, and laboratory features for COPD exacerbation, PE and aspergillosis have been discussed.


Asunto(s)
Aspergilosis Pulmonar Invasiva/etiología , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Embolia Pulmonar/etiología , Infarto Pulmonar/etiología , Anciano de 80 o más Años , Algoritmos , Anticoagulantes/uso terapéutico , Antifúngicos/uso terapéutico , Broncodilatadores/uso terapéutico , Complicaciones de la Diabetes/diagnóstico , Complicaciones de la Diabetes/etiología , Progresión de la Enfermedad , Humanos , Aspergilosis Pulmonar Invasiva/diagnóstico , Aspergilosis Pulmonar Invasiva/tratamiento farmacológico , Aspergilosis Pulmonar Invasiva/microbiología , Masculino , Valor Predictivo de las Pruebas , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Embolia Pulmonar/diagnóstico , Embolia Pulmonar/tratamiento farmacológico , Infarto Pulmonar/diagnóstico , Infarto Pulmonar/tratamiento farmacológico , Factores de Riesgo , Esteroides/uso terapéutico , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Trombosis de la Vena/complicaciones , Trombosis de la Vena/diagnóstico
8.
Eur Respir Rev ; 18(111): 29-34, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20956120

RESUMEN

Prostacyclin and its analogues (prostanoids) are potent vasodilators, and exhibit antithrombotic, antiproliferative and anti-inflammatory properties. Pulmonary arterial hypertension (PAH) is characterised by vasoconstriction, thrombosis and proliferation, and is associated with reduced synthesis of endogenous prostacyclin. This provides a strong rationale for the use of prostanoids to treat PAH, a concept that is now supported by more than two decades of clinical research and experience. Intravenous and subcutaneous prostanoids have clearly demonstrated efficacy in severe PAH, but adverse events related to the drug delivery system, systemic side-effects and tachyphylaxis have driven research into alternative prostanoid treatments. Iloprost is administered by inhalation, and thus avoids most of the systemic side-effects associated with i.v. or subcutaneous prostanoid infusion. Two randomised controlled 12-week trials in patients with PAH have demonstrated efficacy and a favourable safety profile for iloprost as monotherapy (the AIR trial) and in combination with oral bosentan (STEP). Open-label uncontrolled long-term studies of inhaled iloprost therapy indicate that this treatment may improve long-term outcomes in PAH.


Asunto(s)
Iloprost/administración & dosificación , Infarto Pulmonar/tratamiento farmacológico , Vasodilatadores/administración & dosificación , Administración por Inhalación , Ensayos Clínicos como Asunto , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...